KraneShares MSCI All China Health Care Index ETF
Name
As of 11/01/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
Vitals
YTD Return
-13.3%
1 yr return
-17.9%
3 Yr Avg Return
-20.3%
5 Yr Avg Return
-5.7%
Net Assets
$50.6 M
Holdings in Top 10
43.9%
52 WEEK LOW AND HIGH
Expenses
OPERATING FEES
Expense Ratio 0.79%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 45.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 11/01/2024Price
Aum/Mkt Cap
YIELD
Exp Ratio
Watchlist
KURE - Profile
Distributions
- YTD Total Return -13.3%
- 3 Yr Annualized Total Return -20.3%
- 5 Yr Annualized Total Return -5.7%
- Capital Gain Distribution Frequency Annually
- Net Income Ratio -0.25%
- Dividend Yield 0.8%
- Dividend Distribution Frequency Annual
Fund Details
-
Legal NameKraneShares MSCI All China Health Care Index ETF
-
Fund Family NameKrane Funds Advisors, LLC
-
Inception DateJan 31, 2018
-
Shares Outstanding5448971
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerJonathan Shelon
Fund Description
Under normal circumstances, the Fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in instruments in its Underlying Index or in instruments that have economic characteristics similar to those in the Underlying Index. The Underlying Index is a free float adjusted market capitalization weighted index, subject to the 10/40 Constraint (as defined below), which is designed to measure the equity market performance of Chinese companies in the healthcare sector, as classified by the Global Industry Classification Standard. The securities eligible for inclusion in the Underlying Index include all types of publicly issued shares of Chinese issuers, such as A-Shares, B-Shares, H-Shares, P-Chips and Red Chips, which are described below. The issuers included in the Underlying Index may include mid-cap and large-cap companies.
To determine the investable universe of Chinese equity securities for the Underlying Index, the index provider, MSCI, Inc. (“Index Provider”), applies investability screens to securities within the healthcare sector based on the MSCI Global Investable Market Indexes Methodology, along with MSCI’s investability and minimum size criteria for emerging markets. To be included in the Underlying Index, at the time of each rebalance, securities must, among other things: (1) be within the top 85% of the investable universe (based on market capitalization); and (2) meet certain liquidity requirements as measured by the three-month annual traded value ratio, the twelve-month annual traded value ratio and three-month frequency of trading percentage.
Underlying Index constituents are weighted by the security’s free-float adjusted market capitalization, as calculated based on MSCI’s Foreign Inclusion Factor (“FIF”) and subject to Foreign Ownership Limits (“FOLs”), but is modified so that, as of the rebalance date, no issuer constitutes more than 10% of the Underlying Index and so that the cumulative weight of all constituents with a weight of over 5% does not exceed 40% of the Underlying Index (“10/40 Constraint”). The FIF of a security is defined as the proportion of shares outstanding that is available for investment in the public equity markets by foreign investors. For China A-Shares, an FIF of 100% is applied to their free-float adjusted market capitalization for calculating their final weight in the Underlying Index. The FOL of a security is defined as the proportion of share capital of the security that is available for purchase to foreign investors.
The Fund may invest up to 20% of its assets in instruments that are not included in the Underlying Index, but that Krane believes will help the Fund track the Underlying Index. These investments may include equity securities and depositary receipts of issuers whose securities are not constituents of the Underlying Index, derivative instruments (including swaps, futures, forwards, structured notes and options), other investment companies (including exchange traded funds or “ETFs”) and cash or cash equivalents (including money market funds). The other investment companies in which the Fund may invest may be advised, sponsored or otherwise serviced by Krane and/or its affiliates.
The following China-related securities may be included in the Underlying Index and/or represent investments of the Fund:
● | China A-Shares, which are shares of companies incorporated in mainland China that are traded on the Chinese exchanges and denominated in domestic renminbi. China A-Shares are primarily purchased and sold in the domestic Chinese market. To the extent the Fund invests in China A-Shares, it expects to do so through the trading and clearing facilities of a participating exchange located outside of mainland China (“Stock Connect Programs”). A Qualified Foreign Investor (“QFI”) license may also be acquired to invest directly in China A-Shares. |
● | China B-Shares, which are shares of companies listed on the Shanghai or Shenzhen Stock Exchange but quoted and traded in foreign currencies (such as Hong Kong Dollars or U.S. Dollars), which were primarily created for trading by foreign investors. |
● | China H-Shares, which are shares of companies incorporated in mainland China and listed on the Hong Kong Stock Exchange (“H-Shares”), where they are traded in Hong Kong dollars and may be traded by foreign investors. |
● | China N-Shares, which are shares of companies with business operations in mainland China and listed on an American stock exchange, such as NYSE or NASDAQ (“N-Shares”). |
● | P-Chips, which are shares of private sector companies with a majority of their business operations in mainland China and controlling private Chinese shareholders, which are incorporated outside of mainland China and traded on the Hong Kong Stock Exchange in Hong Kong dollars. |
● | Red Chips, which are shares of companies with a majority of their business operations in mainland China and controlled by the central, provincial or municipal governments of the PRC, whose shares are traded on the Hong Kong Stock Exchange in Hong Kong dollars. |
● | S-Chips, which are shares of companies with business operations in mainland China and listed on the Singapore Exchange. S-Chip shares are issued by companies incorporated anywhere, but many are registered in Singapore, the British Virgin Islands, the Cayman Islands, or Bermuda. |
Although the Fund expects to replicate (or hold all constituents of) the Underlying Index, the Fund reserves the right to use representative sampling to track the Underlying Index. “Representative sampling” is a strategy that involves investing in a representative sample of securities that collectively have an investment profile similar to the Underlying Index.
As of May 31, 2024, the Underlying Index included 71 securities of companies with a market capitalization range of approximately $1.86 billion to $48.56 billion and an average market capitalization of approximately $7.47 billion. The Underlying Index is rebalanced quarterly and whenever the 10/40 Constraint is breached, which may occur due to market movements.
The Fund is non-diversified. To the extent the Underlying Index is concentrated in a particular industry, the Fund is expected to be concentrated in that industry. The Underlying Index includes securities of issuers engaged in the healthcare sector, but its exposure to the industries within that sector are not fixed and subject to change.
The Fund may engage in securities lending.
KURE - Performance
Return Ranking - Trailing
Period | KURE Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -13.3% | -14.0% | 32.3% | 100.00% |
1 Yr | -17.9% | -17.0% | 38.8% | 100.00% |
3 Yr | -20.3%* | -21.6% | 6.1% | 98.84% |
5 Yr | -5.7%* | -12.7% | 14.9% | 95.65% |
10 Yr | N/A* | -4.2% | 9.7% | 50.00% |
* Annualized
Return Ranking - Calendar
Period | KURE Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -18.2% | -26.6% | 26.3% | 51.04% |
2022 | -25.5% | -41.6% | -9.4% | 33.33% |
2021 | -26.5% | -52.5% | 26.5% | 90.80% |
2020 | 69.0% | 1.3% | 138.5% | 4.00% |
2019 | 34.0% | -1.9% | 42.6% | 20.55% |
Total Return Ranking - Trailing
Period | KURE Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
YTD | -13.3% | -14.0% | 32.3% | 100.00% |
1 Yr | -17.9% | -17.0% | 38.8% | 100.00% |
3 Yr | -20.3%* | -21.6% | 6.1% | 98.84% |
5 Yr | -5.7%* | -12.7% | 14.9% | 95.65% |
10 Yr | N/A* | -4.2% | 9.7% | N/A |
* Annualized
Total Return Ranking - Calendar
Period | KURE Return | Category Return Low | Category Return High | Rank in Category (%) |
---|---|---|---|---|
2023 | -17.7% | -25.7% | 30.1% | 56.25% |
2022 | -25.4% | -40.4% | -6.8% | 43.33% |
2021 | -15.8% | -48.9% | 29.5% | 73.56% |
2020 | 69.0% | 2.0% | 138.5% | 6.67% |
2019 | 34.3% | 7.8% | 44.4% | 28.77% |
KURE - Holdings
Concentration Analysis
KURE | Category Low | Category High | KURE % Rank | |
---|---|---|---|---|
Net Assets | 50.6 M | 1.06 M | 5.63 B | 48.96% |
Number of Holdings | 69 | 27 | 1176 | 32.29% |
Net Assets in Top 10 | 17.5 M | 477 K | 3.28 B | 56.25% |
Weighting of Top 10 | 43.89% | 5.6% | 85.4% | 66.67% |
Top 10 Holdings
- SHENZHEN MINDRAY BIO-MEDIC-A COMMON STOCK 9.65%
- JIANGSU HENGRUI PHARMACEUT-A COMMON STOCK 6.66%
- BEIGENE LTD COMMON STOCK 4.87%
- CSPC PHARMACEUTICAL GROUP LT COMMON STOCK 4.41%
- WUXI BIOLOGICS CAYMAN INC COMMON STOCK 3.68%
- INNOVENT BIOLOGICS INC COMMON STOCK 3.67%
- ZHANGZHOU PIENTZEHUANG PHA-A COMMON STOCK 3.16%
- WUXI APPTEC CO LTD-A COMMON STOCK 2.69%
- AIER EYE HOSPITAL GROUP CO-A COMMON STOCK 2.60%
- YUNNAN BAIYAO GROUP CO LTD-A COMMON STOCK 2.53%
Asset Allocation
Weighting | Return Low | Return High | KURE % Rank | |
---|---|---|---|---|
Stocks | 97.68% | 51.72% | 100.63% | 44.79% |
Cash | 2.32% | 0.00% | 33.85% | 57.29% |
Preferred Stocks | 0.00% | 0.00% | 2.47% | 20.83% |
Other | 0.00% | -0.02% | 47.32% | 29.17% |
Convertible Bonds | 0.00% | 0.00% | 0.15% | 19.57% |
Bonds | 0.00% | 0.00% | 0.00% | 15.63% |
Stock Sector Breakdown
Weighting | Return Low | Return High | KURE % Rank | |
---|---|---|---|---|
Healthcare | 100.00% | 0.00% | 100.00% | 1.09% |
Utilities | 0.00% | 0.00% | 11.37% | 56.52% |
Technology | 0.00% | 0.00% | 58.02% | 98.91% |
Real Estate | 0.00% | 0.00% | 22.12% | 83.70% |
Industrials | 0.00% | 0.00% | 36.69% | 100.00% |
Financial Services | 0.00% | 0.00% | 41.62% | 92.39% |
Energy | 0.00% | 0.00% | 19.38% | 53.26% |
Communication Services | 0.00% | 0.00% | 41.06% | 89.13% |
Consumer Defense | 0.00% | 0.00% | 20.13% | 97.83% |
Consumer Cyclical | 0.00% | 0.00% | 95.37% | 100.00% |
Basic Materials | 0.00% | 0.00% | 19.86% | 86.96% |
Stock Geographic Breakdown
Weighting | Return Low | Return High | KURE % Rank | |
---|---|---|---|---|
Non US | 95.54% | 0.00% | 99.87% | 15.63% |
US | 2.14% | 0.00% | 100.63% | 73.96% |
KURE - Expenses
Operational Fees
KURE Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Expense Ratio | 0.79% | 0.09% | 14.63% | 77.08% |
Management Fee | 0.78% | 0.09% | 1.50% | 34.38% |
12b-1 Fee | 0.00% | 0.00% | 1.00% | 2.63% |
Administrative Fee | N/A | 0.06% | 0.25% | N/A |
Sales Fees
KURE Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Front Load | N/A | 3.50% | 5.75% | N/A |
Deferred Load | N/A | 1.00% | 1.00% | N/A |
Trading Fees
KURE Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Max Redemption Fee | N/A | 2.00% | 2.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
KURE Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
---|---|---|---|---|
Turnover | 45.00% | 4.00% | 241.00% | 37.97% |
KURE - Distributions
Dividend Yield Analysis
KURE | Category Low | Category High | KURE % Rank | |
---|---|---|---|---|
Dividend Yield | 0.75% | 0.00% | 8.89% | 62.50% |
Dividend Distribution Analysis
KURE | Category Low | Category High | Category Mod | |
---|---|---|---|---|
Dividend Distribution Frequency | Annual | Annual | Annual | Annual |
Net Income Ratio Analysis
KURE | Category Low | Category High | KURE % Rank | |
---|---|---|---|---|
Net Income Ratio | -0.25% | -1.76% | 3.66% | 65.22% |
Capital Gain Distribution Analysis
KURE | Category Low | Category High | Capital Mode | |
---|---|---|---|---|
Capital Gain Distribution Frequency | Annually | Annually | Annually | Annually |
Distributions History
Date | Amount | Type |
---|---|---|
Dec 18, 2023 | $0.113 | OrdinaryDividend |
Dec 28, 2022 | $0.010 | OrdinaryDividend |
Dec 29, 2021 | $4.054 | OrdinaryDividend |
Dec 29, 2020 | $0.000 | OrdinaryDividend |
Dec 27, 2019 | $0.057 | OrdinaryDividend |
Dec 26, 2018 | $0.037 | OrdinaryDividend |
Dec 26, 2018 | $0.039 | CapitalGainShortTerm |
KURE - Fund Manager Analysis
Managers
Jonathan Shelon
Start Date
Tenure
Tenure Rank
Aug 01, 2018
3.83
3.8%
Jonathan Shelon, Managing Partner and Chief Operating Officer at Krane, also serves as a portfolio manager of each Fund and supports Mr. Schlarbaum and Krane’s investment team with respect to each Fund. Mr. Shelon has been a portfolio manager of each Fund since August 2018 (in the case of KraneShares CSI China Internet ETF, KraneShares Electric Vehicles and Future Mobility Index ETF, KraneShares Emerging Markets Consumer Technology Index ETF, KraneShares MSCI All China Healthcare Index ETF, KraneShares MSCI All China Index ETF, KraneShares MSCI China Environment Index ETF, KraneShares MSCI One Belt One Road Index ETF and KraneShares Zacks New China ETF) or since inception (in the case of KraneShares Emerging Markets Healthcare Index ETF, KraneShares MSCI All China Consumer Discretionary Index ETF, KraneShares MSCI All China Consumer Staples Index ETF and KraneShares MSCI China A Inclusion Hedged Index ETF,). Mr. Shelon joined Krane in 2015 as a Managing Partner. Mr. Shelon has spent the majority of his career managing investment portfolios and diverse teams at leading asset management organizations. Most recently, he was the Chief Investment Officer of a 40-person global Specialized Strategies Team at J.P. Morgan with $40 billion AUM. Prior to joining J.P. Morgan, Mr. Shelon spent ten years as a portfolio manager at Fidelity Investments since 2001 where he was responsible for the investment performance, process and evolution of their target-date strategies for retirement savings, college savings and income generation. Prior to joining, he was a quantitative consultant at Callan Associates, Inc.
James Maund
Start Date
Tenure
Tenure Rank
Jan 14, 2020
2.38
2.4%
James Maund, Head of Capital Markets at Krane Funds Advisors LLC. He joined the Krane Funds Advisors in 2020 and has been in the investment management industry since 2005. Previously, he was a Vice President in the Institutional ETF Group and a member of the ETF Capital Markets Group at State Street Global Advisors (2010-2019); and an ETF trader at Goldman Sachs & Co (2005-2010). Mr. Maund graduated with a bachelor’s degree in economics from Wesleyan University.
Tenure Analysis
Category Low | Category High | Category Average | Category Mode |
---|---|---|---|
0.09 | 24.1 | 3.67 | 3.22 |